FRAXA's mission is to find specific treatments and ultimately a cure for Fragile X syndrome. We aim to bring practical treatment into current medical practice as quickly as possible; we prioritize projects that have a clear practical application and the results of which will be shared in a timely fashion. FRAXA awards Clinical Trial Grants. These grants are strictly for clinical research with human subjects who have Fragile X. This grant is flexible in amount, structure, and duration, but may be subject to some negotiation. Emphasis will be placed on clinical trials of potentially disease-modifying agents which have been previously validated in Fragile X animal models, especially in previous FRAXA-funded research. Other types of clinical research will also be considered, such as biomarker studies in Fragile X patients, or trials of symptomatic therapies, but this type of research is a lower priority. There is no limit to the structure of the grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or time-frame (though all grants over one year still need yearly renewal). The application must be submitted as a single PDF to both Dr. Michael Tranfaglia and Katie Clapp. Please provide the following information with your application: Project title; Lay description suitable for publishing on Fraxa;s website if project is funded; Requested start date; Budget; Scientific description of the proposed project; Curriculum Vitae for the Principal Investigator; Curriculum Vitae for the Fellow and/or other personnel to be supported under the grant; three references who are willing to be contacted to provide recommendations for the candidate fellow; and full accounting of any other current and submitted sources of support for this project and other lab research. A Letter of Intent submitted to Dr. Michael Tranfaglia is essential before submitting any application. Applications are accepted and reviewed on a rolling basis, so there is no application deadline. Please visit the award's website or contact the FRAXA Research Foundation for more information.